Atlas Trials

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

Clinical trial NCT06905301 · RECRUITING

Trial details

NCT number
NCT06905301
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Study type
OBSERVATIONAL
Breast Cancer
Start date
2026-01-23
Primary completion
2029-12-31
Enrollment
240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.